Serina Therapeutics, Inc. 8-K

What Happened
Serina Therapeutics, Inc. (SER) filed a Form 8-K on March 25, 2026 to announce its results of operations and financial condition for the year ended December 31, 2025. The company issued a press release reporting those 2025 financial results (the press release is furnished as Exhibit 99.1 to the filing). The filing is signed by CEO Steve Ledger.

Key Details

• Filing date: March 25, 2026 (Form 8-K, Item 2.02).
• Subject: Announcement of financial results for the year ended December 31, 2025.
• Exhibit provided: Press release (Exhibit 99.1) and interactive XBRL cover page (Exhibit 104).
• Authorized signature: /s/ Steve Ledger, Chief Executive Officer.

Why It Matters
This 8-K formally notifies investors that Serina’s full-year 2025 financial results and management commentary are available in the company’s press release. Investors should review the press release (Exhibit 99.1) for details on revenue, earnings/loss, cash position, and any operational updates that could affect the stock. Also watch for related filings (quarterly or annual reports) that may provide audited figures and additional context.